Bailard Inc. Has $1.89 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN

Bailard Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,601 shares of the biopharmaceutical company’s stock after selling 433 shares during the quarter. Bailard Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $343,764,000. Pacer Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company’s stock worth $258,366,000 after acquiring an additional 390,374 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 234.7% during the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after acquiring an additional 326,583 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after purchasing an additional 174,056 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Regeneron Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 1.1%

Shares of Regeneron Pharmaceuticals stock opened at $681.72 on Thursday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $823.56. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $593.81 and a two-hundred day moving average price of $569.58. The stock has a market capitalization of $71.65 billion, a P/E ratio of 16.32, a PEG ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter last year, the firm posted $12.46 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective on the stock. UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, Morgan Stanley decreased their target price on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research report on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $796.57.

Insiders Place Their Bets

In related news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.